Table 2.

Multivariate analysis for validating the prognostic performance for recurrence-free survival of the 12-gene signature measured from FFPE samples after adjusting for other patient characteristics in the 166 ADC patients without ACT.

	HR	pv
Smoking status (Yes vs. No)	9.54 (1.3, 69.93)	0.026
Age (Year)	1.00 (0.96, 1.04)	0.88
Gender (M vs. F)	1.84 (0.99, 3.41)	0.054
Size (>=4cm vs. < 4cm)	1.76 (0.62, 4.97)	0.28
Stage (II vs. I)	2.30 (0.84, 6.30)	0.11
Group (High-risk vs. Low-risk)	4.20 (2.01, 8.79)	0.00014